Follow-up Report on the Diagnosis of Diabetes Mellitus

National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28: 1039–1057, 1979

World Health Organization: Diabetes Mellitus: Report of a WHO Study Group. Geneva, World Health Org., 1985 (Tech. Rep. Ser., no. 727)

The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20: 1183–1197, 1997

World Health Organization: Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva, World Health Org., 1999

DECODE Study Group on Behalf of the European Diabetes Epidemiology Study Group: Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. BMJ 317: 371–375, 1998

Larsson H, Berglund G, Lindgarde F, Ahren B: Comparison of ADA and WHO criteria for diagnosis and glucose intolerance (Letter). Diabetologia 41: 1124–1125, 1998

Davies MJ, Raymond NT, Day JL, Hales CN, Burden AC: Impaired glucose tolerance and the fasting hyperglycaemia have different characteristics. Diabet Med 17: 433–440, 2000

Rathmann W, Giani G, Mielck A: Cardiovascular risk factors in newly diagnosed abnormal glucose tolerance: comparison of 1997 ADA and 1985 WHO criteria (Letter). Diabetologia 42: 1268–1269, 1999

Hanefield M, Temelkova-Kurktschiev T, Schaper F, Henkel E, Siegert G, Koehler C: Impaired fasting glucose is not a risk factor for atherosclerosis. Diabet Med 16: 212–218, 1999

The DECODE Study Group, the European Diabetes Epidemiology Group: Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161: 397–404, 2001

The DECODE Study Group, on behalf of the European Diabetes Epidemiology Group: Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascuar and noncardiovascular diseases? Diabetes Care 26: 688–696, 2003

Little RR: Glycated hemoglobin standardization: National Glycohemoglobin Standardization Program (NGSP) Perspective (Review). Clin Chem Lab Med. In Press

Peters AL, Davidson MB, Schriger DL, Hasselblad V: A clinical approach for the diagnosis of diabetes mellitus: an analysis using glycosylated hemoglobin levels: Meta-analysis Research Group on the Diagnosis of Diabetes Using Glycated Hemoglobin Levels. JAMA 276: 1246–1252, 1996

Rohlfing CL, Little RR, Wiedmeyer H, England JD, Madsen R, Harris MI, Flegal KM, Eberhardt MS, Goldstein DE: Use of GHb (HbA1c) in screening for undiagnosed diabetes in the U. S. population. Diabetes Care 23: 187–191, 2000

Wang W, Lee ET, Fabsitz R, Welty TK, Howard BV: Using HbA1c to improve efficacy of the American diabetes association fasting plasma glucose criterion in screening for new type 2 diabetes in American Indians. Diabetes Care 25: 1365–1370, 2002

Barr RG, Nathan DM, Meigs JB, Singer DE: Tests of glycemia for the diagnosis of type 2 diabetes mellitus. Ann Intern Med 137: 263–272, 2002

Ko G, Chan J, Yeung V, Chow C, Tsang L, Li J, So W, Wai H, Cockram C: Combined use of a fasting plasma glucose concentration and HbA1c or fructosamine predicts the likelihood of having diabetes in high-risk subjects. Diabetes Care 21: 1221–1225, 1998

Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: 1343–1350, 2001

Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393–403, 2002

Wenying Y, Lixiang L, Jimevu Q, Zhiqing Y, Haicheng P, Guofeng H, et al: The preventative effect of acarbose and metformin on the progression to diabetes mellitus in the IGT population: a 3 year multicenter prospetive study. Clin J Endocrinol Metab 17: 131–135, 2001

Chiasson JL, Josse Rg, Gomis R, Hanefeld M, Karasik A, Laakso M: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 359: 2072–2077, 2002

Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP: Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51: 2796–2803, 2002

Rusforth NB, Bennett PH, Miller M: Fasting and two-hour post-blood glucose levels for the diagnosis of diabetes: the relationship between glucose levels and complications of diagetes in the Pima Indians. Diabetologia 16: 373–379, 1970

Zimmet P, Whitehouse S: Bimodality of fasting and two-hour glucose tolerance distributed in a Micronesian population. Diabetes 27: 793–800, 1970

Smith NL, Barzilay JI, Shaffer D, Savage PJ, Heckbert SR, Kuller LH, Kronmal RA, Resnick HE, Psaty BM: Fasting and 2-hour postchallenge serum glucose measures and risk of incident cardiovascular events in the elderly: the Cardiovascular Health Study. Arch Intern Med 162: 209–216, 2002

Gabir MM, Hanson RL, Dabelea D, Imperatore G, Roumain J, Bennett PH, Knowler WC: The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 23: 1108–1112, 2000

Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS: Comparison of diabetes diagnostic categories in the U. S. population according to 1997 American Diabetes Association and 1980–1985 World Health Organization diagnostic criteria. Diabetes Care 20: 1859–1862, 1997

Shaw JE, Zimmet PZ, Hodge AM, de Courten M, Dowse GK, Chitson P, Tuomilehto J, Alberti KGMM: Impaired fasting glucose: how low should it go? Diabetes Care 23: 34–39, 2000

Burtis CA, Ashwood ER: Tietz Textbook of Clinical Chemistry. 3rd ed. Philadelphia, W.B. Saunders, 1999, p. 782

Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M: Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 48: 436–472, 2002

Unwin N, Shaw J, Zimmet P, Alberti KGMM: Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 19: 708–723, 2002

Bortheiry AL, Malerbi DA, Franco LJ: The ROC curve in the evaluation of fasting capillary blood glucose as a screening test for diabetes and IGT. Diabetes Care 17: 1269–1272, 2002

Dyson PA, Hammersley MS, Morris RJ, Holman RR, Turner RC: The Fasting Hyperglycaemia Study. II. Randomized controlled trial of reinforced healthy-living advice in subjects with increased but not diabetic fasting plasma glucose. Metabolism 46 (12 Suppl. 1): 50–55, 2002

Sacks DB: College of American Pathologists Glycohemoglobic Survey 2002. Set GH2-A, CAP2000

Coutinho M, Gerstein HC, Wang Y, Yusuf S: The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 22: 233–240, 1997

Balkau B, Bertrais S, Ducimetiere P, Eschwege E: Is there a glycemic threshold for mortality risk? Diabetes Care 22: 696–699, 1997

Bjornholt JV, Erikssen G, Aaser E, Sandvik L, Nitter-Hauge S, Jervell J, Erikssen J, Thaulow E: Fasting blood glucose: an underestimated risk factor for cardiovascular death: results from a 22-year follow-up of healthy nondiabetic men. Diabetes Care 22: 45–49, 1999

Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H: Coronary-heart-disease risk and impaired glucose tolerance: the Whitehall study. Lancet 1: 1373–1376, 1980

Saydah SH, Miret M, Sung J, Varas C, Gause D, Brancati FL: Postchallenge hyperglycemia and mortality in a national sample of U. S. adults. Diabetes Care 24: 1397–1402, 2001

Eschwege E, Charles MA, Simon D, Thibult N, Balkau B: From policemen to policies: what is the future for 2-h glucose? The Kelly West Lecture, 2000. Diabetes Care 24: 1945–1950, 2001

de Vegt F, Dekker JM, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ: Similar 9-year mortality risks and reproducibility for the World Health Organization and American Diabetes Association glucose tolerance categories: the Hoorn Study. Diabetes Care 23: 40–44, 2000

de Vegt F, Dekker JM, Ruhe HG, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ: Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 42: 926–931, 1999

The DECODE Study Group, European Diabetes Epidemiology Group: Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe: glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354: 617–621, 1999

Barzilay JI, Spiekerman CF, Wahl PW, Kuller LH, Cushman M, Furberg CD, Dobs A, Polak JF, Savage PJ: Cardiovascular disease in older adults with glucose disorders: comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria. Lancet 354: 622–625, 1999

Barrett-Connor E, Ferrara A: Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men: the Rancho Bernardo Study. Diabetes Care 21: 1236–1239, 1998

Rodriguez BL, Lau N, Burchfiel CM, Abbott RD, Sharp DS, Yano K, Curb JD: Glucose intolerance and 23-year risk of coronary heart disease and total mortality: the Honolulu Heart Program. Diabetes Care 22: 1262–1265, 1999

Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study. Diabetes Care 22: 920–924, 1999

Shaw JE, Hodge AM, de Courten M, Chitson P, Zimmet PZ: Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. Diabetologia 42: 1050–1054, 1999

Gabir M, Hanson RL, Debelea D, Imperatore G, Rousmain J, Bennett PH, Knowler WC: Plasma glucose and prediction of microvascular disease and mortality: evaluation of 1997 American Diabetes Association and 1999 World Health Organization criteria for diagnosis of diabetes. Diabetes Care 23: 1113–1118, 2000

Balkau B, Forhan A, Eschwege E: Two hour plasma glucose is not unequivocally predictive for early death in men with impaired fasting glucose: more results from the Paris Prospective Study. Diabetologia 45: 1224–1230, 2002

Meigs JB, Nathan DM, D’Agostino RB Sr, Wilson PW: Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 25: 1845–1850, 2002

Stern MP, Fatehi P, Williams K, Haffner SM: Predicting future cardiovascular disease: do we need the oral glucose tolerance test? Diabetes Care 25: 1851–1856, 2002

Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP: Excess mortality among individuals with impaired glucose tolerance (IGT) is limited to those who develop diabetes: the San Antonio Heart Study (Abstract). Diabetes 51 (Suppl. 2): A229, 2002

UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837–853, 1998

Chiasson J-L, Josse RG, Gormis R, Hanefeld M, Karasik A, Laakso M, the STOP-NIDDM Trial Research Group: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290: 486–494, 2003

Harris MI, Eastman RC: Early detection of undiagnosed diabetes mellitus: a US perspective. Diabetes Metab Res Rev 16: 230–236, 2000

American Diabetes Association: Standards of medical care for patients with diabetes mellitus. Diabetes Care 26 (Suppl. 1): S33–S50, 2003

Bogardus C, Lillioja S, Howard BV, Reaven G, Mott D: Relationships between insulin secretion, insulin action, and fasting plasma glucose concentration in nondiabetic and noninsulin-dependent diabetic subjects. J Clin Invest 74: 1238–1246, 1984

Ferrannini E, Bjorkman O, Reichard GA Jr, Pilo A, Olsson M, Wahren J, DeFronzo RA: The disposal of an oral glucose load in healthy subjects: a quantitative study. Diabetes 34: 580–588, 1985

DeFronzo RA: Lilly Lecture 1987: the triumvirate: beta-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 37: 667–687, 1988

Weyer C, Bogardus C, Pratley RE: Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 48: 2197–2203, 1999

Reaven GM: Banting Lecture 1988: role of insulin resistance in human disease. Diabetes 37: 1595–1607, 1988

Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK: Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 263: 2893–2898, 1990

Edwards KL, Austin MA, Newman B, Mayer E, Krauss RM, Selby JV: Multivariate analysis of the insulin resistance syndrome in women. Arterioscler Thromb 14: 1940–1945, 1994

Meigs JB, D’Agostino RB Sr, Wilson PW, Cupples LA, Nathan DM, Singer DE: Risk variable clustering in the insulin resistance syndrome: the Framingham Offspring Study. Diabetes 46: 1594–1600, 1997

Gray RS, Fabsitz RR, Cowan LD, Lee ET, Howard BV, Savage PJ: Risk factor clustering in the insulin resistance syndrome: the Strong Heart Study. Am J Epidemiol 148: 869–878, 1998

Hanson RL, Imperatore G, Bennett PH, Knowler WC: Components of the “metabolic syndrome” and incidence of type 2 diabetes. Diabetes 51: 3120–3127, 2002

Tuomilehto J: Point: a glucose tolerance test is important for clinical practice. Diabetes Care 25: 1880–1882, 2002

Davidson MB: Counterpoint: the oral glucose tolerance test is superfluous. Diabetes Care 25: 1883–1885, 2002

Feskens EJ, Bowles CH, Kromhout D: Intra- and interindividual variability of glucose tolerance in an elderly population. J Clin Epidemiol 44: 947–953, 1991

McDonald GW, Fisker GF, Burnham C: Resproducibility of the oral glucose tolerance test. Diabetes 14: 473–480, 1965

Olefsky JM, Reaven GM: Insulin and glucose responses to identical oral glucose tolerance tests performed forty-eight hours apart. Diabetes 23: 449–453, 1974

Mooy JM, Grootenhuis PA, de Vries H, Kostense PJ, Popp-Snijders C, Bouter LM, Heine RJ: Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study. Diabetologia 39: 298–305, 1996

Ko GT, Chan JC, Woo J, Lau E, Yeung VT, Chow CC, Cockram: The reproducibility and usefulness of the oral glucose tolerance test in screening for diabetes and other cardiovascular risk factors. Ann Clin Biochem 35: 62–67, 1998

Burke JP, Haffner SM, Gaskill SP, Williams KL, Stern MP: Reversion from type 2 diabetes to nondiabetic status: influence of the 1997 American Diabetes Association criteria. Diabetes Care 21: 1266–1270, 1998

Eschwege E, Charles MA, Simon D, Thibult N, Balkau B: Reproducibility of the diagnosis of diabetes over a 30-month follow-up: the Paris Prospective Study. Diabetes Care 24: 1941–1944, 2001

Stern MP, Williams K, Haffner SM: Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med 136: 575–581, 2002

Ruige JB, de Neeling JN, Kostense PJ, Bouter LM, Heine RJ: Performance of an NIDDM screening questionnaire based on symptoms and risk factors. Diabetes Care 20: 491–496, 1997

Baan CA, Ruige JB, Stolk RP, Witteman JC, Dekker JM, Heine RJ, Feskens EJ: Performance of a predictive model to identify undiagnosed diabetes in a health care setting. Diabetes Care 22: 213–219, 1999

Lindstrom J, Tuomilehto J: The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 26: 725–731, 2003